Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tibet Weixinkang Medicine Co., Ltd. (603676.SS)
Lhasa, CN
Tibet Weixinkang Medicine Co., Ltd., a pharmaceutical enterprise headquartered in Lhasa, China, is dedicated to the entire lifecycle of medicinal products within the country, encompassing their research and development, manufacturing, and sales. The company's diverse range of offerings includes specialized vitamins for parenteral nutrition, electrolyte solutions, intravenous iron preparations, antibiotic medications, and therapies designed for digestive system and liver conditions. Among its specific injectable products are multivitamins, potassium magnesium aspartate, iron sucrose, and potassium aspartate. Established in 2006, the firm operated under the name Weixinkang Medicine Youxian Gongsi until its rebranding to Tibet Weixinkang Medicine Co., Ltd. occurred in 2015.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.11% | -4.35% | -12.92% | -17.81% | -18.32% | -12.26% | -17.07% | -38.71% | +11.20% | +15.95% | +15.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-12.7% Q1'26: +8.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-5.3% Q1'26: -20.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.7% Q1'26: +23.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+25.0% ★ Q1'26: +25.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+46.5% ★ Q1'26: +55.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.02× ★ Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|
| Revenue |
1.40B
est: 1.47B (-4.9%)
|
1.32B
est: 1.64B (-19.3%)
|
1.30B
est: 1.94B (-32.8%)
|
1.14B
est: 2.27B (-49.9%)
|
| EBITDA |
218.81M
est: 252.94M (-13.5%)
|
258.96M
est: 281.65M (-8.1%)
|
323.26M
est: 401.43M (-19.5%)
|
334.69M
est: 469.86M (-28.8%)
|
| EBIT |
182.54M
est: 196.93M (-7.3%)
|
216.18M
est: 219.29M (-1.4%)
|
276.83M
est: 335.86M (-17.6%)
|
283.83M
est: 393.11M (-27.8%)
|
| Net Income |
176.96M
est: 198.66M (-10.9%)
|
214.02M
est: 228.89M (-6.5%)
|
246.17M
est: 284.60M (-13.5%)
|
232.85M
est: 383.78M (-39.3%)
|
| SGA |
480.20M
est: 369.57M (+29.9%)
|
401.02M
est: 411.53M (-2.6%)
|
344.45M
est: 568.04M (-39.4%)
|
206.95M
est: 664.87M (-68.9%)
|
| EPS |
0.41
est: 0.46 (-10.9%)
|
0.50
est: 0.53 (-5.7%)
|
0.57
est: 0.66 (-13.6%)
|
0.54
est: 0.89 (-39.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Liu | Vice Chairman & Deputy GM | — | male |
| Haibo Yu | Board Secretary | — | male |
| Liqun Yao | Accounting Supervisor | — | — |
| Shigong Chen | Deputy GM & Director | — | male |
| Xiaobing Zhou | Deputy General Manager | — | male |
| Yanxia Zheng | Financial Director | — | female |
| Yong Zhang | Chairman of the Board & GM | — | male |
| Zizhong Weng | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603676.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
